"10.1371_journal.pone.0092273","plos one","2014-04-07T00:00:00Z","Ikuo Nakamura; Kais Zakharia; Bubu A Banini; Dalia S Mikhail; Tae Hyo Kim; Ju Dong Yang; Catherine D Moser; Hassan M Shaleh; Sarah R Thornburgh; Ian Walters; Lewis R Roberts","Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America; Bristol-Myers Squibb, Wallingford, Connecticut, United States of America","Conceived and designed the experiments: IN KZ BB DM ST LR. Performed the experiments: IN KZ BB DM TK CM HS ST. Analyzed the data: IN KZ BB DM JY CM ST LR. Contributed reagents/materials/analysis tools: ST IW. Wrote the manuscript: IN KZ BB DM ST LR.","Dr. Ian Walters is employed by Bristol Myers Squibb, the funder of this study, and has stock holdings in the company. He played a role in study design and in review/editing of the manuscript, but had no role in data collection and analysis or in the decision to publish. Brivanib is under development by Bristol Myers Squibb. This does not alter the authors' adherence to the PLoS ONE policies on sharing data and materials.","2014","04","Ikuo Nakamura","IN",11,TRUE,6,8,8,6,TRUE,TRUE,FALSE,0,NA,FALSE
